INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR

Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that are inhibitors of inhibitors of epidermal growth factor receptor (EGFR), including EGFR C797S mutants. Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or...

Full description

Saved in:
Bibliographic Details
Main Authors ROBERTS, Tucker Curran, DADA, Raphael Oluwagbemiga, CHANG, Jae Hyuk, PHAM, Johnny D, POLAT, Dilan Emine, NEIGER, Estelle, VEKARIYA, Rakesh Harsukhlal, NDUBAKU, Chudi, CRIFAR, Cynthia Charlene, GIBBONS, Paul Anthony, ROMERO, F. Anthony, BLANK, Brian R, SILVA, Hugo de Almeida, TAKASAKI, Harumi, JEANNERET, Alexandria Daria Maria, BROWN, William, MCINTOSH, Kyle Conner
Format Patent
LanguageEnglish
French
Published 04.05.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that are inhibitors of inhibitors of epidermal growth factor receptor (EGFR), including EGFR C797S mutants. Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Formula (I) La divulgation concerne des composés de formule (I), ou un sel pharmaceutiquement acceptable de ceux-ci, qui sont des inhibiteurs d'inhibiteurs du récepteur du facteur de croissance épidermique (EGFR), y compris des mutants de l'EGFR C797S. La divulgation concerne également des compositions pharmaceutiques comprenant les composés de formule (I), ou des sels pharmaceutiquement acceptables de ceux-ci, ainsi qu'un ou plusieurs excipients pharmaceutiquement acceptables. La divulgation concerne en outre des méthodes de traitement du cancer chez un sujet nécessitant un tel traitement, comprenant l'administration au sujet d'une dose d'un composé de formule (I), ou d'un sel pharmaceutiquement acceptable de celui-ci. Formule (I)
Bibliography:Application Number: WO2022US78570